Listed by the USPTO as THOMAE, EVAN GODFREY
Tech Center 1600 • Art Units: 1623
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18950743 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18824564 | NEW PYRIDINIUM SALT-BASED CHEMICALS AS BIOCIDE AND THEIR USE | Non-Final OA | Saudi Arabian Oil Company |
| 19069015 | TOPICAL FORMULATIONS FOR THERAPEUTICALLY ACTIVE AGENTS | Non-Final OA | OCuSOFT, Inc. |
| 18874166 | NOVEL RAS INHIBITORS | Non-Final OA | KHR BIOTEC GMBH |
| 18821273 | THE ANTI-INFLAMMATORY ROLE OF CANNABIDIOL, RETINYL PALMITATE, BETA-CARYOPHYLLENE AND TRIBUTYRIN WHEN ADMINISTERED IN CONJUNCTION | Non-Final OA | FLG Sciences, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your StrategyEvan Godfrey Thomae examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
